Antibody-based therapeutics in oncology

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• The success of therapeutic antibodies like rituximab and trastuzumab has spurred interest in antibody-based cancer treatments.
• Antibodies offer potential advantages over small molecules, including lower toxicity and improved efficacy when conjugated with radioisotopes or toxins.

Purpose of the Study:

• To review the structure, antigenicity, efficacy, and toxicity of anticancer therapeutic antibodies.
• To discuss conjugation strategies, including radioisotopes and toxins, for enhanced antibody therapeutics.
• To examine antibody target validation for improved clinical performance in cancer treatment.

Main Methods:

• Review of existing literature on anticancer antibody therapeutics.
• Analysis of antibody structure and methods to reduce antigenicity.
• Evaluation of conjugation techniques and target validation approaches.

Main Results:

• Anticancer antibodies are a growing area of therapeutics for various cancers.
• Conjugation strategies are expanding the market with novel radiolabeled and toxin-linked products.
• Despite numerous agents in development, only a select few achieve regulatory approval and market success.

Conclusions:

• Antibody therapeutics, alone or in combination, are expected to play a significant role in cancer treatment.
• Conjugation strategies will continue to evolve, offering new treatment options.
• Careful consideration of antibody structure, antigenicity, target validation, and conjugation is crucial for developing successful antibody-based cancer drugs.